Clinical Characteristics of Study Subjects.

Overall p values are listed on the table.a Secondary analysis: control vs. aviremic p0.05.b Effect of gender was evaluated by Chi Square test.c Secondary analyses were calculated by Fisher's exact test: control vs. aviremic p = 0.23, control vs. viremic p = 0.12, aviremic vs. viremic p = 1.00.d Non-Caucasian = African-American, Asian/Pacific Islander, Native American, Hispanic, or Other; overall p value calculated by Chi Square test.e Secondary analyses were calculated by Fisher's exact test: control vs. aviremic p = 0.04, control vs. viremic p = 0.06, aviremic vs. viremic p = 0.63.f Antiretroviral therapy: 1 medication = NRTI, ≥3 medications = 1 PI+2 NRTI or NNRTI+2 NRTI.g Control n = 9, aviremic n = 6, viremic n = 15.h Secondary analyses: control vs. viremic 0.010.05.i Secondary analyses: aviremic vs. viremic p0.05.j Immunoglobulins were measured in supernatants from 105 unstimulated PBMC cultured in RPMI+10% heat-inactivated fetal calf serum for 7 days, control n = 5, aviremic n = 6, viremic n = 7.k Secondary analyses: control vs. viremic p0.05.l Secondary analyses: control vs. aviremic p0.05.